OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone. OXiGENE Inc (NASDAQ:OXGN) stock performance was -2.56% in last session and finished the day at $4.18. Traded volume was 9,288,070 million shares in the last session and the average volume of the stock remained 1.06 million shares. The beta of the stock remained 2.72. OXiGENE Inc (NASDAQ:OXGN) insider ownership is 0.10%.
Research analysts at Deutsche Bank boosted their target price on shares of Tesaro Inc (NASDAQ:TSRO) to $72.00 in a report released on Thursday, American Banking and Market News reports. TESARO Inc (NASDAQ:TSRO) rose 27.49 percent to $38.86 yesterday on volume of 3.46 million shares. The intra-day range of the stock was $31.50 to $40.99. TESARO Inc (NASDAQ:TSRO) has a market capitalization of $1.40 billion.
Discovery Laboratories, Inc. (NASDAQ:DSCO) on Mar. 13 announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. The Company reported a net loss of $11.7 million ($0.16 per share) on 73.1 million weighted-average common shares outstanding for the quarter ended December 31, 2013, compared to a net loss of $6.8 million ($0.16 per share) on 43.5 million weighted-average common shares outstanding for the comparable period in 2012. Discovery Laboratories, Inc. (NASDAQ:DSCO)’s stock on Mar13, 2014 reported a decrease of -11.15% to the closing price of $2.31. Its fifty two weeks range is $1.50 -$3.05. The total market capitalization recorded $195.19 million. The overall volume in the last trading session was 2,190,683 million shares. In its share capital, Discovery Laboratories, Inc. (NASDAQ:DSCO) has 54.79 million outstanding shares.
Albany Molecular Research (NASDAQ:AMRI) was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday,Analyst Ratings Network.com reports. On Thursday, shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) advanced 5.85% to close the day at $17.18. Company return on investment (ROI) is 6.20% and its monthly performance is recorded as 54.77%. Albany Molecular Research, Inc. (NASDAQ:AMRI) quarterly revenue growth is 61.92%.